Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain

  1. Balañá, C.
  2. Vaz, M.A.
  3. Lopez, D.
  4. De La Peñas, R.
  5. García-Bueno, J.M.
  6. Molina-Garrido, M.J.
  7. Sepúlveda, J.M.
  8. Cano, J.M.
  9. Bugés, C.
  10. Sanz, S.M.
  11. Arranz, J.L.
  12. Perez-Segura, P.
  13. Rodriguez, A.
  14. Martin, J.M.
  15. Benavides, M.
  16. Gil, M.
Zeitschrift:
Clinical and Translational Oncology

ISSN: 1699-048X 1699-3055

Datum der Publikation: 2014

Ausgabe: 16

Nummer: 3

Seiten: 273-279

Art: Artikel

DOI: 10.1007/S12094-013-1068-3 GOOGLE SCHOLAR